Drug
Ubrogepant clinical trials
Also written UBRELVY and MK-1602.
- studies test it
- 15
- open now
- 2
- in phase 3
- 7
- first study started
- 2012
Keep track of what changes. Save the ubrogepant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2016 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 5 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 2
- Phase 3
- 7
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 2
AbbVie (7) · Allergan (6) · Chicago Headache Center & Research Institute (1) · Universitaire Ziekenhuizen KU Leuven (1)
Often tested with
Tested in the same studies.
Atogepant (2) · Sumatriptan (1) · Erenumab (1) · Galcanezumab (1)
Studies
Open first, then newest update. How each study uses ubrogepant is read from its arms, and is right about nine times in ten.
Testing it · 15
- Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)RecruitingPhase 3AbbVieNCT05125302Written as Ubrogepant
- Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)Enrolling by invitationPhase 3AbbVieNCT05127954Written as Ubrogepant
- Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult ParticipantsActive, not recruitingPhase 1AbbVieNCT07680686Written as Ubrogepant
- Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineActive, not recruitingPhase 3AbbVieNCT06417775Written as Ubrogepant
- Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With MigraineCompletedPhase 4AbbVieNCT05264129Written as Ubrogepant
- Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodiesActive, not recruitingPhase 4Chicago Headache Center & Research InstituteNCT05503082Written as Ubrogepant 50 MG [Ubrelvy]
- Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult ParticipantsCompletedPhase 3AbbVieNCT04492020Written as Ubrogepant 100 mg
- Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and CapsaicinCompletedNot applicableUniversitaire Ziekenhuizen KU LeuvenNCT05654298Written as Ubrogepant
- Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of MigraineCompletedPhase 1AbbVieNCT04818515Written as Ubrogepant
- Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With MigraineCompletedPhase 1AllerganNCT04179474Written as Ubrogepant
- An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of MigraineCompletedPhase 3AllerganNCT02873221Written as Ubrogepant
- Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of MigraineCompletedPhase 3AllerganNCT02867709Written as Ubrogepant
- A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)CompletedPhase 2AllerganNCT01613248Written as MK-1602
- Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of MigraineCompletedPhase 3AllerganNCT02828020Written as Ubrogepant
- A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)CompletedPhase 2AllerganNCT01657370Written as MK-1602
Given in every arm · 1 — ubrogepant is usual care beside what is tested
As the comparator · 2 — what is tested is compared with ubrogepant
- Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of MigraineTerminatedPhase 4Messoud Ashina, MDNCT05214001Written as Ubrogepant 50Mg Tab
- Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult VolunteersCompletedPhase 1AbbVieNCT05892757Written as Ubrogepant
Codes
What other systems call ubrogepant · ClinicalTrials.gg INT000647
- MeSH (NLM) C000615620ubrogepantConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) AD0O8X2QJRUBROGEPANTConfirmed FDA, NLM, Wikidata
- RxNorm 2268216One source FDA
- Wikidata Q27273878ubrogepantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152790UbrogepantOne source FDA
- DrugBank DB15328One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000615620 | ubrogepant | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | AD0O8X2QJR | UBROGEPANT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2268216 | — | One source FDA |
| Wikidata | Q27273878 | ubrogepant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152790 | Ubrogepant | One source FDA |
| DrugBank | DB15328 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.